Women who suffer greater menopause symptoms are more likely to experience memory and thinking problems as they age, research has suggested.Experts found that women who recalled a heavier burden of ...

Posters presented at the Association of Cancer Care Centers opening session covered initiatives to boost clinical trial ...

Trading commencing on the OTC Markets on March 5, 2025.Trading expected to continue under ticker symbol "NKGN" for common stock and "NKGNW" for warrants.NKGen Biotech, Inc. ("NKGen" or the "Company") ...

Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape. CS5001 is also being ...

For an abdominal wall hernia repair, also known as a ventral hernia repair, the most common surgical approaches have been ...

President Donald Trump’s pick to lead the National Institutes of Health answered sharp questions in a confirmation hearing ...

Income tax expense increased by $6.7 million in 2024 compared to 2023, primarily due to an increase in U.S. taxes under the ...

Ocugen (NASDAQ: OCGN) Q4 2024 Earnings Call Mar 05, 2025, 8:30 a.m. ET ...

Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to accelerating promising treatments, has announced enrollment of the first two pa ...

Discover 7 biotech companies in Taiwan, a rising regional player in precision medicine, immunotherapy, and drug development!

OPGx-MERTK is a gene therapy being developed by Opus Genetics to treat patients impacted by MERTK-related retinitis pigmentosa (RP). Results from a pre-clinical study which evaluated OPGx-MERTK in a ...